Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase

Chemical Biology and Drug Design

Volumn 72, Issue 5, 2008, Pages 360-369

  Lagos, Carlos F ^a   Caballero, Julio ^b   Gonzalez Nilo, Fernando D ^b   David Pessoa Mahana, Carlos ^a   Perez Acle, Tomas ^a,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD DE TALCA   (Chile)

^c Fundacion Ciencia para la Vida   (Chile)

Author keywords

Bisphenylbenzimidazole derivatives; Docking; Non nucleoside HIV 1 reverse transcriptase inhibitors; Quantitative structure activity relationship; Radial distribution function descriptors

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BISPHENYLBENZIMIDAZOLE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG PROTEIN BINDING; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BENZIMIDAZOLES; BINDING SITES; COMPUTER SIMULATION; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN STRUCTURE, TERTIARY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 54249140977     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00716.x     Document Type: Article

References (47)

1. De Clercq E. (2004) Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers 1 : 44 64.
2. Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J., Friedman J.M., Rice P.A., Steitz T.A. (1994) Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 91 : 3911 3915.
3. Ren J., Esnouf R., Hopkins A., Ross C., Jones Y., Stammers D., Stuart D (1995) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 3 : 915 926.
4. Sluis-Cremer N., Temiz N.A., Bahar I. (2004) Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2 : 323 332.
5. Chimirri A., Grasso S., Molica C., Monforte A.M., Monforte P., Zappala M., Scopelliti R. (1996) Anti-HIV agents. IV. Synthesis and in vitro anti-HIV activity of novel 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazoles. Farmaco 51 : 279 282.
6. Chimirri A., Grasso S., Monforte A.M., Monforte P., Zappala M. (1991) Anti-HIV agents II. Synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. Farmaco 46 : 925 933.
7. Chimirri A., Grasso S., Monforte A.M., Monforte P., Zappala M. (1991) Anti-HIV agents I. Synthesis and anti-HIV evaluation of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. Farmaco 46 : 817 823.
8. Chimirri A., Monforte P., Rao A., Zappala M., Monforte A.M., De Sarro G., Pannecouque C., Witvrouw M., Balzarini J., De Clercq E. (2001) Synthesis, biological activity, pharmacokinetic properties and molecular modelling studies of novel 1H,3H-oxazolo[3,4-a]benzimidazoles: non-nucleoside HIV-1 reverse transcriptase inhibitors. Antivir Chem Chemother 12 : 169 174.
9. Rao A., Chimirri A., De Clercq E., Monforte A.M., Monforte P., Pannecouque C., Zappala M. (2002) Synthesis and anti-HIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Farmaco 57 : 819 823.
10. Roth T., Morningstar M.L., Boyer P.L., Hughes S.H., Buckheit R.W. Jr., Michejda C.J. (1997) Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-aryl-substituted benzimidazoles. J Med Chem 40 : 4199 4207.
11. Barreca M.L., Carotti A., Carrieri A., Chimirri A., Monforte A.M., Calace M.P., Rao A. (1999) Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg Med Chem 7 : 2283 2292.
12. Kroeger Smith M.B., Hose B.M., Hawkins A., Lipchock J., Farnsworth D.W., Rizzo R.C., Tirado-Rives J., Arnold E., Zhang W., Hughes S.H., Jorgensen W.L., Michejda C.J., Smith R.H. Jr. (2003) Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues. J Med Chem 46 : 1940 1947.
13. Barreca M.L., Rao A., De Luca L., Iraci N., Monforte A.M., Maga G., De Clercq E., Pannecouque C., Balzarini J., Chimirri A. (2007) Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem Lett 17 : 1956 1960.
14. Basavapathruni A., Anderson K.S. (2006) Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly. Curr Pharm Des 12 : 1857 1865.
15. Daeyaert F., de Jonge M., Heeres J., Koymans L., Lewi P., Vinkers M.H., Janssen P.A. (2004) A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets. Proteins 54 : 526 533.
16. Das K., Lewi P.J., Hughes S.H., Arnold E. (2005) Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 88 : 209 231.
17. Yadav A., Kumar Singh S. (2005) Common binding mode for structurally and chemically diverse non-nucleosidic HIV-1RT inhibitors. J Mol Struct (Theochem) 723 : 205 209.
18. Morningstar M.L., Roth T., Farnsworth D.W., Smith M.K., Watson K., Buckheit R.W. Jr., Das K., Zhang W., Arnold E., Julias J.G., Hughes S.H., Michejda C.J. (2007) Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J Med Chem 50 : 4003 4015.
19. Kroeger Smith M.B., Rouzer C.A., Taneyhill L.A., Smith N.A., Hughes S.H., Boyer P.L., Janssen P.A., Moereels H., Koymans L., Arnold E., Ding J., Das K., Zhang W., Michejda C.J., Smith R.H. Jr. (1995) Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Sci 4 : 2203 2222.
20. Jalali-Heravi M., Parastar F. (2000) Use of artificial neural networks in a QSAR study of anti-HIV activity for a large group of HEPT derivatives. J Chem Inf Comput Sci 40 : 147 154.
21. Hannongbua S., Pungpo P., Limtrakul J., Wolschann P. (1999) Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors J Comput Aided Mol Des 13 : 563 577.
22. Duchowicz P.R., Fernández M., Caballero J., Castro E.A., Fernández F.M. (2006) QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem 14 : 5876 5889.
23. Leonard J.T., Roy K. (2003) QSAR Modeling of anti-HIV activities of alkenyldiarylmethanes using topological and physicochemical descriptors. Drug Des Discov 18 : 165 180.
24. Rawal R.K., Kumar A., Siddiqi M.I., Katti S.B. (2007) Molecular docking studies on 4-thiazolidinones as HIV-1 RT inhibitors. J Mol Model 13 : 155 161.
25. Ragno R., Artico M., De Martino G., La Regina G., Coluccia A., Di Pasquali A., Silvestri R. (2005) Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active n-(2-hydroxyethyl) carboxamide and n-(2-hydroxyethyl)carbohydrazide derivatives. J Med Chem 48 : 213 223.
26. Medina-Franco J.L., Golbraikh A., Oloff S., Castillo R., Tropsha A. (2005) Quantitative structure-activity relationship analysis of pyridinone HIV-1 reverse transcriptase inhibitors using the k nearest neighbor method and QSAR-based database mining. J Comput Aided Mol Des 19 : 229 242.
27. Berman H.M., Battistuz T., Bhat T.N., Bluhm W.F., Bourne P.E., Burkhardt K., Feng Z. et al. (2002) The Protein Data Bank. Acta Crystallogr D Biol Crystallogr 58 : 899 907.
28. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. (1983) CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem 4 : 187 217.
29. Halgren T.A. (1999) MMFF VI. MMFF94s option for energy minimization studies. J Comp Chem 20 : 720 729.
30. Wu G., Robertson D.H., Brooks C.L. III., Vieth M. (2003) Detailed analysis of grid-based molecular docking: A case study of CDOCKER - a CHARMm-based MD docking algorithm. J Comp Chem 24 : 1549 1562.
31. Vieth M., Cummins D.J. (2000) DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors. J Med Chem 43 : 3020 3032.
32. Vieth M., Hirst J.D., Kolinski A., Brooks C.L. III. (1998) Assessing energy functions for flexible docking. J Comp Chem 19 : 1612 1622.
33. Vieth M., Hirst J.D., Dominy B.N., Daigler H., Brooks C.L. III. (1998) Assessing search strategies for flexible docking. J Comp Chem 19 : 1623 1631.
34. Bohm H.J. (1994) The development of a simple empirical scoring function to estimate the binding constant for a protein ligand complex of known 3-dimensional structure. J Comput Aided Mol Des 8 : 243 256.
35. Bohm H.J. (1998) Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J Comput Aided Mol Des 12 : 309 323.
36. Kauffman G.W., Jurs P.C (2001) QSAR and k-nearest neighbor classification analysis of selective cyclooxygenase-2 inhibitors using topologically-based numerical descriptors. J Chem Inf Comput Sci 41 : 1553 1560.
37. Gasteiger J., Sadowski J., Schuur J., Selzer P., Steinhauer L., Steinhauer V. (1996) Chemical information in 3D space. J Chem Inf Comput Sci 36 : 1030 1037.
38. Gasteiger J., Schuur J., Selzer P., Steinhauer L., Steinhauer V. (1997) Finding the 3D structure of a molecule in its IR spectrum. Fresenius J Anal Chem 359 : 50 55.
39. González M.P., Caballero J., Tundidor-Camba A., Helguera A.M., Fernández M. (2006) Modeling of farnesyltransferase inhibition by some thiol and non-thiol peptidomimetic inhibitors using genetic neural networks and RDF approaches. Bioorg Med Chem 14 : 200 213.
40. González M.P., Teran C., Fall Y., Teijeira M., Besada P. (2005) A radial distribution function approach to predict A(2B) agonist effect of adenosine analogues Bioorg Med Chem 13 : 601 608.
41. Helguera A.M., Cabrera-Pérez M.A., González M.P. (2006) A radial-distribution-function approach for predicting rodent carcinogenicity. J Mol Model 12 : 769 780.
42. Fernández M., Caballero J. (2006) Ensembles of Bayesian-regularized genetic neural networks for modeling of acetylcholinesterase inhibition by huprines. Chem Biol Drug Des 68 : 201 212.
43. Fernández M., Carreiras M.C., Marco J.L., Caballero J. (2006) Modeling of acetylcholinesterase inhibition by tacrine analogues using Bayesian-regularized genetic neural networks and ensemble averaging. J Enzyme Inhib Med Chem 21 : 647 661.
44. Fernández M., Caballero J., Fernández L., Abreu J.I., Garriga M. (2007) Protein radial distribution function (P-RDF) and Bayesian-regularized genetic neural networks for modeling protein conformational stability: chymotrypsin inhibitor 2 mutants. J Mol Graph Model 26 : 748 759.
45. Hawkins D.M. (2004) The problem of overfitting. J Chem Inf Comput Sci 44 : 1 12.
46. Golbraikh A., Tropsha A. (2002) Beware of q2!. J Mol Graphics Model 20 : 269 276.
47. Roy P., Roy K. (2008) On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 27 : 302 313.